Skip to Content

Polatuzumab Vedotin (Polivy), Rituximab (Rituxan), Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP)

Treatment Given by Infusion, Treatment Taken by Mouth

Generic : Polatuzumab Vedotin (POH-lah-TOO-zoo-mab veh-DOH-tin), Rituximab (rih-TUK-sih-mab), Cyclophosphamide (SY-kloh-FOS-fuh-mide), Doxorubicin (DOK-soh-ROO-bih-sin) and Prednisone (PRED-nih-sone)
Brand : Polivy (poh-LIH-vee), Rituxan (rih-TUK-sun), Cytoxan (sai-TAAK-sn) and Adriamycin (AY-dree-uh-MY-sin)
Download In :
Download 0.39MB
Last Update : February 16, 2026

About this Treatment

The combination of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is used for certain types of lymphoma.

What are Patient Education Sheets (PES)?

A Patient Education Sheet (PES) is a practical tool created with the unique needs of patients with cancer in mind. Each sheet translates complex treatment information into clear, patient-friendly language. They provide easy-to-follow medication schedules and guidance on managing potential side effects, helping patients and their caregivers feel informed and supported.

These resources are pulled directly by healthcare providers, who can download and print them for distribution during patient visits. This ensures that patients and caregivers leave the clinic with a reliable, easy-to-understand reference tailored to their treatment.

In addition to the standard content, PES documents are also editable in designated sections. Providers can add personalized details such as counseling notes, local resources, or contact information, making each sheet specific to the patient’s care journey.